21th PAGE Meeting

Venice - Italy
5-8 June, 2012

View abstracts

Home / 2012 – Venice – Italy / Abstracts

← Back to filters

Abstracts (21)

I-06Sergei Leonov

Optimal design of population pharmacokinetic/pharmacodynamic studies

Wednesday 10:15-11:45

I-08

Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients

Wednesday 10:15-11:45

I-18Mathilde Marchand

How to support a definitive bioequivalence study design using modeling and simulation

Wednesday 10:15-11:45

I-19John Maringwa

Model-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF)

Wednesday 10:15-11:45

I-24Veronese Mattia

Optimal Experimental Design for receptor drug development with PET studies

Wednesday 10:15-11:45

I-31Ricardo Nalda-Molina

Stochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of Doripenem

Wednesday 10:15-11:45

I-40Joakim Nyberg

The robustness of global optimal designs

Wednesday 10:15-11:45

II-21Alexandre Sostelly

Dose and dose schedule optimization of anticancer drugs

Wednesday 15:10-16:40

II-32Daniel Tatosian

Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study

Wednesday 15:10-16:40

II-39Wanchana Ungphakorn

Development of Sparse Sampling Study of Oral Ciprofloxacin for Severely Malnourished Children

Wednesday 15:10-16:40

II-40Pyry Välitalo

Optimal design for a population pharmacokinetic study of oxycodone in preterm neonates, neonates and infants

Wednesday 15:10-16:40

II-47Anders Viberg

Using modeling and simulation to evaluate placebo run-in for pain studies

Wednesday 15:10-16:40

III-25Emma Bostrom

Modeling and Simulation of Pharmacokinetics and H3 Receptor Occupancy for Dose Setting in a Phase IIa Study

Thursday 10:05-11:35

III-61

Optimal two-stage design for a population pharmacokinetic study in children

Thursday 10:05-11:35

III-62Jeroen Elassaiss-Schaap

Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP

Thursday 10:05-11:35

III-66Mathieu Felices

Dose Regimen Assessement For Oral Fexinidazole

Thursday 10:05-11:35

IV-14Bill Gillespie

From Evidence Synthesis to Trial Optimization: The adsim Package for Model-based Simulation in Alzheimer’s Disease

Thursday 15:00-16:30

IV-20Nathalie Gosselin

Simultaneous Optimization of Sampling Strategies for Parent and Metabolite Data Taking into Account a Body Weight Distribution: Applications to Paediatric Studies

Thursday 15:00-16:30

IV-29Eva Hanze

Comparison of longitudinal data analysis to end of treatment data analysis when evaluating precision in dose-exposure-response in neuropathic pain studies.

Thursday 15:00-16:30

IV-50Matts Kågedal

Improved dose selection for PET occupancy studies

Thursday 15:00-16:30

IV-61Anders Kristoffersson

Robust optimal design of ciprofloxacin time-kill curve experiments with respect to autocorrelation

Thursday 15:00-16:30